NANOSTRUCTURED DRUG MARKET ANALYSIS

Nanostructured Drug MarketSize and Trends

Nanostructured Drug Market Dynamics

Nanostructured drugs are gaining significant traction in research and development due to the benefits offered by them in terms of bioavailability, drug stability, shelf-life and dosage. Effective and safe drug delivery is a major challenge in biotechnology and pharmaceutical manufacturers. Novel techniques such as nanotechnology are being introduced by companies to produce innovative product, which is driving growth of the nanostructured drug market. For instance, in 2015, the Food and Drug Administration (FDA) approved Onivyde, an irinotecan liposome injection by merrimack pharmaceuticals, which is a prescription medicine used to treat pancreatic cancer. Onivyde is administered in combination with two other drugs, leucovorin and fluorouracil. Onivyde consists of a chemotherapy drug called irinotecan, which interrupts cell reproduction. Irinotecan is trapped into a nanostructure called liposome. Liposomes are programmed to release drug slowly within the interval of time.

Moreover, increased funding and revenue from nano-enabled products have propelled growth of nanostructured drug market. For instance, According to the National Science Foundation 2014 market report, the global funding for emerging nanotechnology increased by 40% to 45% for past three years. Furthermore, worldwide revenue generated by nano-enabled products have been increased from US$ 339 billion in 2010 to US$ 731 billion in 2012, and to more than US$1 trillion in 2013.

Market- Trends